The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide

Abstract

This analysis indicates that over a 10-year period, as much as $93.1 million per annual cohort is saved by the use of combination therapy for the treatment of severe lupus nephritis.